                         SEQUENCE LISTING

<110>  The Board of Trustees of the Leland Stanford Junior 
       University
 
<120>  COMBINATION THERAPY FOR CANCER

<130>  STAN-1657WO

<150>  63/059,673
<151>  2020-07-31

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  28
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  NeoPCRF1 oligonucleotide


<220>
<221>  source
<222>  (1)..(28)
<223>  sequence is synthesized

<400>  1
ggtttccaaa tgtgtcagtt tcatagcc                                          28


<210>  2
<211>  28
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  StanfordU2 3R oligonucleotide


<220>
<221>  source
<222>  (1)..(28)
<223>  sequence is synthesized

<400>  2
tctgaaacat agttccctaa gacatcag                                          28


<210>  3
<211>  25
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  StanfordU2 5cko oligonucleotide


<220>
<221>  source
<222>  (1)..(25)
<223>  sequence is synthesized

<400>  3
atcatcaatg cttagccaag ccaag                                             25


<210>  4
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cryptic integrin-binding site

<400>  4

Ser Val Val Tyr Gly Leu Arg 
1               5           


<210>  5
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  OPN-FL

<400>  5

Arg Gly Asp Ser Val Val Tyr Gly Leu Arg Ser Lys Ser Lys Lys Phe 
1               5                   10                  15      


Arg Arg 
        


<210>  6
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  OPN-R

<400>  6

Arg Gly Asp Ser Val Val Tyr Gly Leu Arg 
1               5                   10  


<210>  7
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  OPN-CTF

<400>  7

Ser Lys Ser Lys Lys Phe Arg Arg 
1               5               


<210>  8
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  OPN-L

<400>  8

Arg Gly Asp Ser Val Val Tyr Gly Leu 
1               5                   


